Document is current
Any future updates will be listed below
-
Authors
Kim, Won Seog
Oki, Yasuhiro
Kim, Seok Jin
Yoon, Sang Eun
Ardeshna, Kirit M.
Lin, Yi
Ruan, Jia
Porcu, Pierluigi
Brammer, Jonathan E.
Jacobsen, Eric D.
Yoon, Dok Hyun
Suh, Cheolwon
Suarez, Felipe
Radford, John
Budde, Lihua E.
Kim, Jin Seok
Bachy, Emmanuel
Lee, Hun Ju
Bollard, Catherine M.
Jaccard, Arnaud
Kang, Hye Jin
Inman, Shannon
Murray, Maryann
Combs, Katherin E.
Lee, Daniel Y.
Advani, Ranjana
Gunter, Kurt C.
Rooney, Cliona M.
Heslop, Helen E.
-
Funding
Funding for this research was provided by:
Kuur Therapeutics (1)
Kuur Therapeutics (1)
- License Information
-
More Information
Article History
Received: 24 January 2021
Accepted: 13 May 2021
First Online: 24 July 2021
Declarations
:
: Cliona Rooney is a co-founder of AlloVir and Marker Therapeutics and receives research support from Tessa Therapeutics. Helen Heslop is a co-founder with equity in AlloVir and Marker Therapeutics; has served on Advisory Boards for Gilead Biosciences, Novartis, Tessa Therapeutics, Kiadis, Mesoblast, and PACT Pharma; and receives research support from Tessa Therapeutics and Kuur Therapeutics.
